Neoadjuvant selpercatinib for advanced medullary thyroid cancer

BACKGROUND: Targeted kinase inhibitors have been increasingly utilized in the treatment of advanced medullary thyroid cancer (MTC) over the last decade. Recently, highly potent next generation selective RET inhibitors have been clinically validated, and selpercatinib was recently Food and Drug Admin...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Head Neck
Main Authors: Jozaghi, Yelda, Zafereo, Mark, Williams, Michelle D., Gule‐Monroe, Maria K., Wang, Jennifer, Grubbs, Elizabeth G., Vaporciyan, Ara, Hu, Mimi I., Busaidy, Naifa, Dadu, Ramona, Waguespack, Steven G., Subbiah, Vivek, Cabanillas, Maria
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2020
Teme:
Case Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7756223/
https://ncbi.nlm.nih.gov/pubmed/33169506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.26527
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki